FDA Publishes New Product-Specific Guidances To Facilitate Generic Drug Development

The U.S. Food and Drug Administration continue to strengthen its commitment to generic drug development by publishing new and revised Product-Specific Guidance’s (PSGs).

This guidance is designed to:

• Improve regulatory transparency 
• Accelerate development timelines 
• Reduce uncertainty for manufacturers 
• Enhance patient access to affordable medicines 

As competition in the pharmaceutical market increases, PSGs play a critical role in enabling efficient and compliant Abbreviated New Drug Application (ANDA) submissions.

What is FDA product-specific guidance’s (PSGs)?
Product-specific guidance (PSGs) are FDA documents that outline recommended approaches for developing generic versions of specific reference listed drugs, including bioequivalence studies, formulation considerations, and regulatory expectations to support ANDA approval.

What Is Product-Specific Guidance’s (PSGs)?

Product-Specific Guidance’s are regulatory documents that outline the FDA’s expectations for developing generic versions of specific Reference Listed Drugs (RLDs).

Key Elements Covered in PSGs

• Bioequivalence (BE) study requirements 
• In vitro and in vivo study design 
• Dissolution testing methods 
• Formulation and manufacturing considerations 
• Analytical method recommendations 

These guidance act as a blueprint for generic drug developers, reducing ambiguity and aligning development strategies with regulatory expectations.

Why PSGs Matter for Generic Drug Development

PSGs are a cornerstone of the FDA’s effort to promote efficient, science-based generic drug approvals.

Benefits of PSGs

Key Features of FDA PSGs

1. Clear Development Roadmaps

PSGs provide detailed recommendations on:

• Study design 
• Sampling strategies 
• Analyte selection 
• Acceptance criteria 

This enables companies to plan development programs with greater confidence.

2. Accelerated Development Timelines

By defining expectations upfront, PSGs help:

• Avoid unnecessary studies 
• Reduce regulatory queries 
• Streamline ANDA submissions 

3. Transparency and Predictability

PSGs ensure a level playing field for all manufacturers by:

• Standardizing requirements 
• Providing publicly available guidance 
• Supporting consistent regulatory decisions 

4. Support for Complex Generics

Recent PSG updates increasingly focus on complex drug products, including:

• Drug-device combination products 
• Modified-release formulations 
• Locally acting drugs 

Recent Updates and Notable Additions

The FDA continues to expand and refine its PSG database to reflect scientific advancements and regulatory needs.

Examples of Recent PSG Updates

These updates highlight FDA’s focus on both traditional and complex generics.

How PSGs Impact Generic Drug Developers

PSGs serve as strategic tools for pharmaceutical companies:

Developer Actions Based on PSGs

Companies can deviate from PSG recommendations if they provide strong scientific justification and engage with the FDA.

Regulatory and Scientific Considerations

Bioequivalence (BE) Requirements

• Pharmacokinetic (PK) studies 
• Comparative clinical endpoint studies (for complex products) 
• In vitro dissolution testing 

Biopharmaceutics Classification System (BCS)

• Enables biowaivers for certain drugs 
• Reduces need for in vivo studies 
• Accelerates development timelines 

Complex Product Challenges

• Device compatibility (e.g., inhalers, injectables) 
• Local drug delivery considerations 
• Advanced analytical method requirements 

Impact on the Pharmaceutical Market

The expansion of PSGs contributes to:

• Increased generic competition 
• Lower drug prices 
• Improved patient access 
• Faster availability of alternatives to branded drugs 

Best Practices for Manufacturers

• Continuously monitor FDA PSG updates 
• Integrate PSG recommendations early in development 
• Conduct robust BE and analytical studies 
• Maintain flexibility for alternative approaches 
• Engage regulatory experts and FDA early 

Quick Facts 

• PSGs guide development of generic drugs 
• Issued by the FDA for specific RLDs 
• Include BE study and formulation recommendations 
• Support ANDA submissions 
• Enable faster and more predictable approvals 

How Maven Scientific Laboratories Supports Generic Drug Development

Our Services

• PSG gap analysis and regulatory strategy 
• Bioequivalence study design and support 
• Analytical method development 
• ANDA submission assistance 
• Regulatory interaction with FDA 

Why Choose Maven

• Expertise in global regulatory frameworks 
• Strong scientific and analytical capabilities 
• Proven track record in generic drug approvals 
• End-to-end lifecycle support 

Accelerate Your Generic Drug Development

Planning a generic drug submission?

Partner with Maven Scientific Laboratories for efficient, compliant, and successful ANDA strategies

1. Reduce development timelines
2. Improve approval success rates
3. Ensure regulatory compliance

Conclusion

The U.S. Food and Drug Administration continue to play a pivotal role in advancing generic drug development through Product-Specific Guidance’s.

By offering clear, science-based recommendations, PSGs reduce uncertainty, promote innovation, and accelerate access to affordable medicines. For manufacturers, leveraging this guidance effectively can be the key to regulatory success and competitive advantage.

FAQs

1. What is FDA PSGs?
Guidance’s outlining development requirements for generic drugs.

2. Who uses PSGs?
Generic drug manufacturers preparing ANDA submissions.

3. Are PSGs mandatory?
No, but they represent FDA’s recommended approach.

4. Can companies deviate from PSGs?
Yes, with proper scientific justification.

5. What do PSGs include?
BE studies, formulation guidance, and testing methods.

6. How can Maven help?
Through regulatory strategy, BE studies, and submission support.